Men with Latent Autoimmune Diabetes and Type 2 Diabetes May Have Different Change Patterns in Free Testosterone

Bo Ding,1 Feng-fei Li,1 Xiao-fang Zhai,1 Lei Ye,2 Yun Hu,1 and Jian-hua Ma1

1Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
2National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore

Correspondence should be addressed to Yun Hu; huyunwuxi@163.com and Jian-hua Ma; majianhua196503@126.com

Received 23 March 2020; Revised 9 June 2020; Accepted 29 June 2020; Published 24 July 2020

Abstract

Objective. Type 2 diabetic (T2D) male patients with low total testosterone (TT) levels are at an increasing risk of all-cause mortality. However, the levels of TT in male patients with latent autoimmune diabetes in adults (LADA) remain largely unknown.

Research Design and Methods. This was a single-center, open, observational study. The inclusion criteria were male patients who were diagnosed with LADA, and sex, body mass index, C-peptide, and glycated hemoglobin (HbA1c) levels matched with those of T2D patients. Islet function/sensitivity and sex hormone concentrations were determined at baseline and 1-year follow-up. The primary endpoint was the changes in androgen levels from baseline to 1-year follow-up in patients with LADA.

Results. Our data showed that TT and Bio-T levels remained unchanged, while FT levels significantly decreased from baseline to 1-year follow-up in patients with T2D. However, TT, Bio-T, and FT concentrations dramatically increased in the LADA group from baseline to 1-year follow-up. Furthermore, a Spearman analysis showed that changes of TT, FT, and Bio-T levels from baseline to endpoint were significantly negatively correlated with Δ homeostasis model assessment-2 IR (ΔHOMA2-IR), respectively.

Conclusions. The FT change patterns in patients with LADA may differ from those in patients with T2D. Our data also indicated the significant negative correlation between insulin sensitivity and changes of TT, FT, and Bio-T levels along with the diabetic duration in patients with T2D and LADA.

1. Introduction

Aging is a well-known risk factor for type 2 diabetes (T2D), causing a decrease in insulin production and sensitivity cells [1, 2]. Endogenous sex hormones decrease in men and women with age [1, 2], which differently modulate glycemic metabolism between the subjects [3]. Evidence indicates that testosterone concentrations are positively correlated to T2D in women but negatively associated in men; women who had high sex hormone-binding globulin (SHBG) levels also benefited more from reducing incidence of T2D than did men [3]. Researchers further observed that high total testosterone (TT) and free testosterone (FT) values have a potential protective role in reducing the risk of T2D in elderly men [4]. In agreement with this study, a prospective study found that low TT levels are associated with an increase in T2D in men [5], especially in obese T2D male patients with or without metabolic syndrome [6]. Moreover, T2D patients with low T levels had poor glycemic control and increased insulin resistance, which may contribute to the longer duration of diabetes [7]. Very recently, researchers confirmed that type 2 diabetic men, especially those with low TT concentrations, have increased all-cause mortality [8, 9], leading to a high prevalence of worsening cardiac function, ischemia, and readmission rate [8].

Few studies have focused on sex hormones in patients with type 1 diabetes (T1D). However, previous data suggest that sex hormone concentrations in men with T1D may not be the same as in those with T2D [10]. A previous study showed that the incidence of TT deficiency in male patients with T1D was similar to that in healthy men [11]. Furthermore, a study demonstrated that patients with T1D have higher levels of TT, FT, and SHBG than those in patients with T2D [12]. However, the increased androgen levels had no correlation with insulin sensitivity in T1D adolescents [13]. The underlying mechanisms may be the increased androgen
Latent autoimmune diabetes in adults (LADA) is the most frequent form of autoimmune diabetes, with a higher prevalence than that of adult-onset T1D [15]. The term "type 1.5 diabetes" describes the clinical features of LADA: patients with LADA lack insulin dependency and positive islet autoantibodies at onset, but with a faster decline in beta cell function, they become insulin dependent during the duration progression [16]. Studies have already demonstrated that sex hormone concentrations differ between patients with T2D and T1D, which play a potential role in the risk of incidence and mortality in the two groups. However, research studies focusing on sex hormone change patterns in patients with LADA are mainly unclear.

Therefore, we performed a single-center, open, retrospective study. In this study, we compared the change in patterns of androgen concentrations between patients with LADA and T2D from baseline to 1-year follow-up.

2. Research Design and Methods

This was a single-center, open, observational study. The study protocol and patient consent forms were approved by the Institutional Ethics Committee of Nanjing First Hospital, Nanjing Medical University, No. 32, Gongqingtuan Road, Nanjing, China (2015KY07). All patients provided written informed consent to participate. The methods were conducted in accordance with the Declaration of Helsinki guidelines, including any relevant details.

The inclusion criteria were drug-naïve male patients who were diagnosed with LADA (n = 10) or T2D (n = 15) at Nanjing First Hospital by research clinicians. The criteria for diagnosis of LADA were proposed by the Chinese Diabetes Society: (1) the presence of any islet autoantibodies (glutamic acid decarboxylase antibody (GADA), and the combination of tyrosine phosphatase-like protein antibody (IA-2A), insulin autoantibody (IAA), and autoantibodies to zinc transporter 8 (ZnT8A), can increase the detection rate); (2) the onset age ≥ 18 years; and (3) a minimum period of 6 months of insulin independence. The exclusion criteria were as follows: (a) patients who used systemic steroidal anti-inflammatory drugs or any drugs that may influence T level in the last 3 months; (b) patients with an acute infection; (c) patients with acute complications of diabetes; and (d) patients with a severe systemic disease or any other condition that is judged by researchers to be unsuitable for this study. All enrolled patients were admitted to Nanjing First Hospital in China between March 2016 and January 2019, and the observation period was 12 months.

2.1. Clinical and Laboratory Assessments. Demographic data in terms of height, weight, and age were recorded at baseline and endpoint. Fasting serum was collected for glucose, glycated hemoglobin (HbA1c), C-peptide, albumin, lipid profiles, TT, and SHBG at baseline and 1-year follow-up, respectively. Bioavailable testosterone (Bio-T) and FT were calculated based on TT, SHBG, and albumin levels. A standard meal test was performed to measure glucose and C-peptide concentrations 120 min after meal loading. HbA1c was measured using a high-performance liquid chromatography assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA). C-peptide was determined by chemiluminescent immunometric assay, which employs the Modular Analytics E170 (Roche Diagnostics GmbH, Mannheim, Germany). TT and SHBG were measured using a chemiluminescent immunometric assay, which employs a UniCel™ Dxl 800 automated analyzer (Beckman Coulter Inc., Brea, CA, USA). Body mass index (BMI) was calculated as weight divided by the square of height (kg/m²). Homeostasis model assessment-2 IR (HOMA2-IR) was calculated as previously described [17]. The inclusion criteria for T2D were age, sex, FBG, HbA1c, and fasting C-peptide (<0.75 ng/mL) [7], matched with LADA patients. All patients enrolled in our study were treated with premixed insulin analog combination with metformin for a year, and the study design was described in the study flow chart (Figure 1).

2.2. Statistical Analysis. Statistical analysis was performed using SPSS 16.0 software (SPSS, Science, Chicago, IL, USA). All variables were tested for normal distribution of the data. Data are presented as the mean ± standard error (SE). A paired sample t-test was used for intragroup comparison, and an independent sample t-test was used for intergroup comparison. A Spearman analysis was employed to analyze the regression relationships. All comparisons were 2-sided at a 5% significance level. A P value of less than 0.05 was considered statistically significant.
to 1-year follow-up. On the other hand, patients with T2D had significantly increased islet function. We also compared insulin sensitivity using the HOMA2-IR index between the two groups. We observed that the HOMA2-IR value significantly increased in patients with T2D from baseline to 1-year follow-up, while in patients with LADA, it remained unchanged (Table 2). Furthermore, our data indicated that patients with LADA had significant improvement in insulin sensitivity from baseline to 1-year follow-up, compared with patients in the T2D group (Table 3).

3. Results

3.1. Demographic and Glucose-Lowering Agent Profiles of Enrolled Patients. From January 2016 to June 2019, 25 male patients with LADA (n = 10) and male patients with T2D (n = 15) were enrolled into this study, and all patients completed this study. The demographic characteristics are described in detail in Table 1. Patients with LADA had similar age, FBG, HbA1c, fasting C-peptide, TC, TG, HDL, and LDL concentrations at baseline compared with patients with T2D, and patients in the T2D group had a significant increase in postprandial C-peptide levels (Table 1). Patients with LADA and T2D need insulin (0.46 ± 0.07 IU/kg, 0.48 ± 0.05 IU/kg, respectively) and metformin (1285.71 ± 267.26 mg, 1285.71 ± 267.26 mg, respectively) to maintain glycemic control at the endpoint.

3.2. Changes in Islet Beta Cell Function and Insulin Sensitivity. Fasting and postprandial C-peptide levels in patients with LADA significantly decreased from baseline to 1-year follow-up. On the other hand, patients with T2D had significantly increased islet function. We also compared insulin sensitivity using the HOMA2-IR index between the two groups. We observed that the HOMA2-IR value significantly increased in patients with T2D from baseline to 1-year follow-up, while in patients with LADA, it remained unchanged (Table 2). Furthermore, our data indicated that patients with LADA had significant improvement in insulin sensitivity from baseline to 1-year follow-up, compared with patients in the T2D group (Table 3).

3.3. Changes in HbA1c and Sex Hormone Levels from Baseline to 1-Year Follow-Up. We further compared the changes in HbA1c and sex hormone levels between the two groups at the endpoint. We observed that the levels of TT, Bio-T, and FT values significantly increased in patients with LADA from baseline to 1-year follow-up. Contrary to the trend in the T2D group, patients with T2D had similar TT and Bio-T levels, with a significant decrease in FT value from baseline to endpoint. We also analyzed the changes in SHBG levels between the two groups from baseline to endpoint. Our data showed that SHBG levels were unchanged within

### Table 1: Demographic characteristics and serum parameters between the two groups at baseline and after 1-year follow-up.

| Items      | LADA Baseline | T2D  | P    | LADA After 1 year | T2D  | P    |
|------------|---------------|------|------|-------------------|------|------|
| Age        | 52.6 ± 17.5   | 49.9 ± 10.2 | 0.63 | 53.6 ± 17.5       | 50.9 ± 10.2 | 0.64 |
| BMI        | 22.2 ± 3.2    | 23.7 ± 2.6 | 0.23 | 22.1 ± 3.3       | 23.8 ± 2.3 | 0.26 |
| Albumin    | 38.5 ± 3.3    | 40.9 ± 1.8 * | 0.03 | 42.2 ± 4.2       | 44.1 ± 3.2 | 0.25 |
| TC         | 4.7 ± 1.2     | 4.8 ± 0.7  | 0.85 | 4.3 ± 0.8        | 4.1 ± 0.4  | 0.51 |
| TG         | 1.0 ± 0.5     | 1.6 ± 1.6  | 0.30 | 1.0 ± 0.7        | 1.2 ± 0.5  | 0.42 |
| HDL-C      | 1.4 ± 0.4     | 1.2 ± 0.3  | 0.31 | 1.6 ± 0.5        | 1.4 ± 0.2  | 0.33 |
| LDL-C      | 2.6 ± 0.7     | 2.2 ± 0.6  | 0.38 | 1.8 ± 0.5        | 1.7 ± 0.3  | 0.58 |

LADA: latent autoimmune diabetes in adults; BMI: body mass index (kg/m²); TC: total cholesterol (mmol/L); TG: total triglycerides (mmol/L); HDL-C: high-density lipoprotein cholesterol (mmol/L); LDL-C: low-density lipoprotein cholesterol (mmol/L).

### Table 2: Islet function and insulin sensitivity between the two groups at baseline and after 1-year follow-up.

| Items      | LADA Baseline | T2D  | P    | LADA After 1 year | T2D  | P    |
|------------|---------------|------|------|-------------------|------|------|
| FBG        | 10.1 ± 4.4    | 8.5 ± 3.6  | 0.38 | 10.4 ± 4.3       | 7.5 ± 1.2  | 0.06 |
| HbA1c      | 10.3 ± 2.6    | 9.3 ± 1.7  | 0.29 | 9.0 ± 2.5        | 8.1 ± 1.2  | 0.24 |
| C-p0 min   | 0.5 ± 0.3     | 0.6 ± 0.2  | 0.14 | 0.2 ± 0.2        | 1.3 ± 0.8 * | 0.001 |
| C-p120 min | 0.6 ± 0.5     | 2.0 ± 0.8 * | 0.001 | 0.3 ± 0.3       | 4.2 ± 1.3 * | 0.001 |
| HOMA2-IR   | 7.3 ± 4.0     | 8.2 ± 4.0  | 0.65 | 3.7 ± 2.8        | 12.7 ± 6.4 * | 0.001 |

LADA: latent autoimmune diabetes in adults; FBG: fasting blood glucose (mmol/L); C-p0 min: C-peptide 0 min (ng/mL); C-p120 min: C-peptide120 min (ng/mL); HOMA2-IR: homoeostasis model assessment-2 insulin resistance.

### Table 3: Changes of A1c, sex hormone, and insulin sensitivity between the two groups (values of 1-year follow-up minus values of baseline).

| Items      | LADA group | T2D group | P values |
|------------|------------|-----------|----------|
| ΔHbA1c     | −1.2 ± 2.3 | −1.4 ± 1.0 | 0.78     |
| ΔTT        | 6.5 ± 4.3  | −1.3 ± 3.9 * | 0.001 |
| ΔFT        | 0.1 ± 0.1  | −0.0 ± 0.1 * | 0.001 |
| ΔBio-T     | 2.9 ± 1.6  | −0.5 ± 1.7 * | 0.001 |
| ΔSHBG      | 0.2 ± 9.5  | 0.1 ± 10.4 | 0.98     |
| ΔHOMA2-IR  | −4.9 ± 5.5 | 4.7 ± 6.5 * | 0.01     |

ΔHbA1c: HbA1c (%); ΔTT: total testosterone (nmol/L); ΔFT: free testosterone (nmol/L); ΔBio-T: bioavailable testosterone (nmol/L); ΔSHBG: sex hormone-binding globulin (nmol/L); ΔHOMA2-IR: HOMA2-IR: homoeostasis model assessment-2 insulin resistance.
the two groups; however, patients with LADA had higher SHBG levels than those of T2D patients at baseline and at the endpoint, respectively (Figure 2).

3.4. Factor(s) That Contributed to Changes in Sex Hormone Levels from Baseline to Endpoint. To identify which factor(s) that contributed to the changes in SHBG, TT, FT, and Bio-T in patients with diabetes, a Spearman analysis was performed. Our data showed that ΔTT, ΔFT, and ΔBio-T levels were significantly positively correlated with GADA levels at baseline (all \( P < 0.05 \)), while being significantly negatively correlated with changes in fasting and postprandial C-peptide concentrations from baseline to endpoint (all \( P < 0.05 \)). We did not observe any correlation relationships regarding ΔSHBG levels with the abovementioned factors. Importantly, we observed a significant negative correlation between HOMA2-IR and ΔTT, ΔFT, and ΔBio-T levels (\( P < 0.05 \)) (Table 4).

4. Discussion

This relatively modest study revealed a novel observation that the FT level change pattern in male patients with LADA differed from age- and sex-matched patients with T2D, which gradually decreased along with the diabetic progression. Our data suggested that the change in insulin sensitivity may contribute to the different change patterns between patients with LADA and T2D. Our data also indicated a significant negative correlation between insulin sensitivity and changes of TT, FT, and Bio-T levels along with the diabetic duration in patients with T2D and LADA.

A systematic review and meta-analysis showed that high SHBG concentrations were associated with a high reduction in incidence of T2D in women (>60 nmol/L) compared with men (>28.3 nmol/L) [3]. In contrast, another study showed that women and men with low circulating SHBG concentrations had a high risk of T2D [18]. The cutoff points for men and women at a high risk for T2D might be SHBG values < 40 and <50 nmol/L, respectively [19]. In this study, we observed that patients with T2D had low SHBG levels (<50 nmol/L), while subjects with LADA had high SHBG values (>50 nmol/L), with no changes along with the 1-year follow-up in each group. However, we found that patients with LADA had significantly increased SHBG levels at onset and endpoint, and low SHBG levels may be a potential risk factor for glycemic control in patients with T2D, independent of both adiponectinemia and insulinemia [20]. We observed that male patients with LADA had significant worsening of fasting glucose control compared to males with T2D at the endpoint. The underlying mechanism for uncontrolled glycemia may be the deterioration of beta cell function and the increased insulin sensitivity in patients with LADA.
Hence, future studies are needed to identify the role of SHBG in regulating glycemia in patients with LADA. In humans, TT status consists of Bio-T and conjugated T, with SHBG and albumin as the two bounding proteins [21]. In serum, FT and T conjugated to albumin are called Bio-T [22]. T plays a potential role in controlling carbohydrate metabolism [23]. It also increases glucose uptake via the activation of glucose transporter (GLUT-4) in the liver, adipose tissue, and muscle [24, 25]. In addition, studies have shown that T increases glycolysis and glycogen synthesis and reduces glycon decomposition of skeletal muscle partially, by enhancing phosphofructokinase and hexokinase [26, 27]. Moreover, T may directly ease the process of glucose stimulation insulin secretion via binding to androgen receptors on islet β cells [28]. Therefore, T plays an important role in regulating glucose control in patients with diabetes. In this study, we observed a difference in androgen change patterns in patients with LADA and T2D. The TT, FT, and Bio-T levels significantly increased in the LADA group, while FT levels significantly decreased in patients with T2D. Furthermore, changes in TT, FT, and Bio-T concentrations significantly increased in the LADA group from baseline to endpoint, while these change directions were opposite in T2D patients. However, the underlying mechanisms of the two different changing tendencies of androgen concentrations should be elucidated in future studies. This has been addressed as a limitation in the study.

It is unclear which of these forms of T status are the most appropriate ones regulating metabolism. Studies showed that TT should be considered an indicator of metabolic syndrome rather than other forms of T should [29]. Our data showed that patients with LADA and T2D had similar TT values at onset. However, we observed a significant increase in TT levels in the LADA group from onset to 1-year follow-up.

Androgens play an important role in both muscle mass and body fat remodeling, both of which are correlated with insulin resistance [23]. However, the relationships between variations in T levels and metabolic conditions remain unclear. A study indicated that the low T level in men was an independent risk factor for metabolic syndrome [30]. Furthermore, most obese T2D patients were found with low T levels [31, 32]. In this study, we observed that androgen levels, especially FT and Bio-T values, in the LADA group were significantly increased, while the body weight remained unchanged from onset to endpoint. This warrants the study identifying the relationship between androgen level and weight gain in subjects with LADA.

In conclusion, The FT change patterns in patients with LADA may differ from those in patients with T2D. Our data indicated that insulin sensitivity may contribute to the different FT change patterns in patients with T2D and LADA.

**Data Availability**

The datasets generated during and/or analyzed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.

**Conflicts of Interest**

The authors declare that they have no conflict of interest.

**Authors’ Contributions**

J.H. M. and Y. L. contributed to the conception and design of the study. F.F. L., B. D., and X.F. Z. contributed to the conduct/data collection. Y. H. and X.F. Z. contributed to the data analysis. F.F. L. and B. D. contributed to the writing of the manuscript and the final approval of the manuscript. Bo Ding, Feng-fei Li, and Xiao-fang Zhai contributed equally to this article.

**References**

[1] K. N. Tonyushkina, S. O’Connor, and N. S. Dunbar, “A novel CaSR mutation presenting as a severe case of neonatal familial hypocalciuric hypercalcemia,” *International Journal of Pediatric Endocrinology*, vol. 2012, no. 1, 2012.

[2] U. Gunasekaran and M. Gannon, “Type 2 diabetes and the aging pancreatic beta cell,” *Aging*, vol. 3, no. 6, pp. 565–575, 2011.

[3] E. L. Ding, Y. Song, V. S. Malik, and S. Liu, “Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis,” *Jama*, vol. 295, no. 11, pp. 1288–1299, 2006.

[4] M. Salminen, T. Vahlberg, I. Raiga, L. Niskanen, S. L. Kivela, and K. Iijala, “Sex hormones and the risk of type 2 diabetes mellitus: a 9-year follow up among elderly men in Finland,” *Geriatrics & Gerontology International*, vol. 15, no. 5, pp. 559–564, 2015.

[5] S. Schipf, R. Haring, N. Friedrich et al., “Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP),” *The aging male: the official journal of the International Society for the Study of the Aging Male*, vol. 14, no. 3, pp. 168–175, 2011.
[6] M. Mohammed, M. Al-Habori, A. Abdulteef, and R. Saif-Ali, "Impact of metabolic syndrome factors on testosterone and SHBG in type 2 diabetes mellitus and metabolic syndrome," Journal of Diabetes Research, vol. 2018, Article ID 4926789, 8 pages, 2018.

[7] J. Y. Oh, E. Barrett-Connor, N. M. Wedick, D. L. Wingard, and B. S. Rancho, "Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study," Diabetes Care, vol. 25, no. 1, pp. 55–60, 2002.

[8] Y. Han, W. Sun, G. Sun et al., "A 3-year observation of testosterone deficiency in Chinese patients with chronic heart failure," Oncotarget, vol. 8, no. 45, pp. 79835–79842, 2017.

[9] N. S. Malipatil, G. Yadegarfar, M. Lunt et al., "Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes," Endocrinology, Diabetes & Metabolism, vol. 2, no. 3, p. e00064, 2019.

[10] B. Daka, T. Rosen, P. A. Jansson, C. A. Larsson, and U. Lindblad, "Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden," Endocrine connections, vol. 2, no. 1, pp. 18–22, 2013.

[11] S. K. Holt, N. Lopushnyan, J. Hotaling et al., "Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC," The Journal of clinical endocrinology and metabolism, vol. 99, no. 9, pp. E1655–E1660, 2014.

[12] R. Tomar, S. Dhindsa, A. Chaudhuri, P. Mohanty, R. Garg, and P. Dandona, "Contrasting testosterone concentrations in type 1 and type 2 diabetes," Diabetes Care, vol. 29, no. 5, pp. 1120–1122, 2006.

[13] M. M. Kelsey, P. Bjornstad, K. McFann, and K. Nadeau, "Testosterone concentration and insulin sensitivity in young men with type 1 and type 2 diabetes," Pediatric diabetes., vol. 17, no. 3, pp. 184–190, 2016.

[14] D. Samara-Boustani, A. Colmenares, C. Elie et al., "High prevalence of hirsutism and menstrual disorders in obese adolescent girls and adolescent girls with type 1 diabetes mellitus despite different hormonal profiles," European journal of endocrinology, vol. 166, no. 2, pp. 307–316, 2012.

[15] M. I. Hawa, H. Kolb, N. Schloot et al., "Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7," Diabetes Care, vol. 36, no. 4, pp. 908–913, 2013.

[16] R. Juneja and J. P. Palmer, "Type 1 1/2 diabetes: myth or reality," Autoimmunity, vol. 29, no. 1, pp. 65–83, 2009.

[17] N. R. Hill, J. C. Levy, and D. R. Matthews, "Expansion of the homeostasis model assessment of-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: iHOMA2," Diabetes Care, vol. 36, no. 8, pp. 2324–2330, 2013.

[18] E. L. Ding, Y. Song, J. A. E. Manson et al., "Sex hormone-binding globulin and risk of type 2 diabetes in women and men," The New England Journal of Medicine, vol. 361, no. 12, pp. 1152–1163, 2009.

[19] M. W. O’Reilly, M. Glisic, B. Kumarendran et al., "Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort," Clinical endocrinology, vol. 90, no. 1, pp. 145–154, 2019.

[20] F. Bonnet, B. Balkau, J. M. Malécot et al., "Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels," European Journal of Endocrinology, vol. 161, no. 1, pp. 81–85, 2009.

[21] A. Morgentaler, A. Traish, G. Hackett, T. H. Jones, and R. Ramasamy, "Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 International Consultation for Sexual Medicine," Sexual Medicine Reviews, vol. 7, no. 4, pp. 636–649, 2019.

[22] D. M. Kelly and T. H. Jones, "Testosterone and obesity," Obesity reviews: an official journal of the International Association for the Study of Obesity, vol. 16, no. 7, pp. 581–606, 2015.

[23] D. M. Kelly and T. H. Jones, "Testosterone: a metabolic hormone in health and disease," The Journal of Endocrinology, vol. 217, no. 3, pp. R25–R45, 2013.

[24] T. Muthusamy, P. Murugesan, and K. Balasubramanian, "Sex steroids deficiency impairs glucose transporter 4 expression and its translocation through defective Akt phosphorylation in target tissues of adult male rat," Metabolism: Clinical and Experimental, vol. 58, no. 11, pp. 1581–1592, 2009.

[25] K. Mitsushashi, T. Senmaru, T. Fukuda et al., "Testosterone stimulates glucose uptake and GLUT4 translocation through LKB1/AMPK signaling in 3T3-L1 adipocytes," Endocrine, vol. 51, no. 1, pp. 174–184, 2016.

[26] K. Sato, M. Iemitsu, K. Aizawa, and R. Ajisaka, "Testosterone and DHEA activate the glucose metabolism-related signaling pathway in skeletal muscle," American Journal of Physiology Endocrinology and Metabolism, vol. 294, no. 5, pp. E961–E968, 2008.

[27] A. Ramamani, M. M. Aruldhas, and P. Govindarajulu, "Differential response of rat skeletal muscle glycogen metabolism to testosterone and estradiol," Canadian Journal of Physiology and Pharmacology, vol. 77, no. 4, pp. 300–304, 1999.

[28] G. Navarro, W. Xu, D. A. Jacobson et al., "ExTRANuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male," Cell Metabolism, vol. 23, no. 5, pp. 837–851, 2016.

[29] M. Tanabe, Y. Akehi, T. Nomiyama, J. Murakami, and T. Yanase, "Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men," Endocrine Journal, vol. 62, no. 2, pp. 123–132, 2015.

[30] M. Naifar, N. Reikik, M. Messedi et al., "Male hypogonadism and metabolic syndrome," Andrologia, vol. 47, no. 5, pp. 579–586, 2015.

[31] S. Dhindsa, M. G. Miller, C. L. McWhirter et al., "Testosterone concentrations in diabetic and nondiabetic obese men," Diabetes Care, vol. 33, no. 6, pp. 1186–1192, 2010.

[32] M. Grossmann, "Low testosterone in men with type 2 diabetes: significance and treatment," The Journal of clinical endocrinology and metabolism, vol. 96, no. 8, pp. 2341–2353, 2011.